Abstract: Chemical entities that modulate PI3 kinase activity, pharmaceutical compositions containing the chemical entities, and methods of using these chemical entities for treating diseases and conditions associated with P13 kinase activity are described herein.

Abstract: The present invention provides compounds of Formula I that modulate PI3 kinase activity and methods of treatment of diseases and conditions associated with PI3 kinase activity.

Abstract: The present invention provides substituted benzimidazole compounds of Formula I: wherein the variables R1, R2, W1, W2, W3, W4, W5, W6, Wa, Wb, Wc and Wd are defined herein. The compounds are useful as phosphoinositide 3-kinase (PI3 kinase) inhibitors.

Abstract: Some aspects include a method of monitoring an acoustic environment of a mobile device operating in a low power mode, the mobile device having a first and second processor, the method comprises receiving acoustic input while the mobile device is operating in the low power mode, performing at least one first processing stage on the acoustic input using the first processor, prior to engaging the second processor, to evaluate whether the acoustic input includes a voice command, performing at least one second processing stage on the acoustic input using the second processor to evaluate whether the acoustic input includes a voice command if further processing is needed to determine whether the acoustic input includes a voice command, and initiating responding to the voice command when either the at least one first processing stage or the at least one second processing stage determines that the acoustic input includes a voice command.

Abstract: The present invention provides chemical entities or compounds and pharmaceutical compositions thereof that are capable of modulating certain protein kinases such as mTor, tyrosine kinases, and/or lipid kinases such as PI3 kinase. Also provided in the present invention are methods of using these compositions to modulate activities of one or more of these kinases, especially for therapeutic applications.

Abstract: A computerized file system is accessible over the Internet or other type of network, in which certain “triggering events” pertaining to the operation of the file system automatically generate a notification message to users. Once a user has been authenticated, this user's access rights are determined. An Automatic Notification function checks to see if any “triggering” events have occurred when a user performs a particular task. The Automatic Notification function defines what type of event will become a triggering event, and also defines what will be the triggering action, once the triggering event occurs, and stores this information in a database. The Auto-notification function can comprise programs that are launched to perform certain tasks. The precise type of auto-notification message is fully configurable for each component in the file system.

Abstract: Heterocyclic entities that modulate PI3 kinase activity, pharmaceutical compositions containing the isoquinolone entities, and methods of using these chemical entities for treating diseases and conditions associated with P13 kinase activity are described herein.

Abstract: The present invention provides for a method for treating a disease condition associated with PI3-kinase a and/or mTOR in a subject. In another aspect, the invention provides for a method for treating a disease condition associated with PI3-kinase a and/or mTOR in a subject. In yet another aspect, a method of inhibiting phosphorylation of both Akt (S473) and Akt (T308) in a cell is set forth. The present invention also provides a pharmaceutical kit effective for treating a disease condition associated with PI3-kinase ? and/or mTOR in a subject.

Abstract: Provided herein are compounds of formula (I-A), (I-B), (I-C), or (I-D), pharmaceutical compositions comprising the compounds, and methods of use thereof. The compounds provided herein modulate kinase activity, including PI3 kinase activity, and are useful for treating diseases and conditions associated with kinase activity, including diseases and conditions associated with PI3 kinase activity.

Abstract: The present invention provides for a method for treating a disease condition associated with PI3-kinase ? and/or mTOR in a subject. In another aspect, the invention provides for a method for treating a disease condition associated with PI3-kinase ? and/or mTOR in a subject. In yet another aspect, a method of inhibiting phosphorylation of both Akt (S473) and Akt (T308) in a cell is set forth.

Abstract: A container for a consumer product and an applicator is disclosed where the container is at least partially constructed of a translucent material and both the consumer product and the applicator are at least partially visible through the translucent material. Also, when the container is displayed at a point of purchase, the applicator is located above the centroid of the consumer product and the applicator covers a portion of the consumer product. The overlap of the applicator and the consumer product is visible through the translucent material.

Abstract: A system may include a computing device configured to access a patient record including screening information indicative of vital signs of a patient and questionnaire information indicative of health history of the patient, determine, using a risk engine based on the screening information and the questionnaire information, risk allocations for the patient that define a primary health risk of the patient, and identify, according to the risk allocations, at least one online course and personal goal to be prescribed to the patient to reduce the primary health risk of the patient toward a health goal.

Abstract: The proposed innovation provides methods and systems for measuring the interpupillary distance. The proposed innovation provides a fitting pad (102) having two detection points (104 and 106). The fitting pad is placed on the forehead of the user and an image is captured. The image is uploaded and pupil distance calculator software locates the fitting detection points and calculates the distance in pixels of the left and right X, Y coordinates. The software creates an image scale by dividing the pixel counts between the detection points. The software automatically locates the X, Y coordinates between the center of the left and right pupils and calculates the distance in pixels. The resulting pixel distance divided by the image scale provides the interpupillary distance in millimeter. In embodiments, segment height is calculated based upon an image imported by the user and the combined scaled images of the user and the frame.

Abstract: The present invention provides for methods and pharmaceutical compositions comprising inhibitors of mTorC1 and/or mTorC2. In some aspects, the invention provides for treatment regimens resulting in enhanced treatment efficacy and better tolerability.

Abstract: A system for restricting operation of wireless devices, for example cell phones, comprises a controller and a plurality of sensors. The system restricts device usage, while permitting emergency phone calls, for example 911 calls. The sensors receive transmissions from devices, and use the transmissions for identification and determining whether a device is within a restricted zone. One disclosed method is triangulation, using time of arrival of transmissions at the sensors. If the device is within the zone, the controller sends device identification, and possibly a customized restriction request, to a remote node, for example a control node of a cell phone network operator. The operator then uses its network resources to implement the requested restrictions. Communication between the controller and the remote node is secure, possibly encrypted, to minimize malicious interference. A wireless control can define vertices of the zone and exempt certain devices from restrictions. Jamming is not required.

Abstract: Chemical entities that modulate PI3 kinase activity, pharmaceutical compositions containing the chemical entities, and methods of using these chemical entities for treating diseases and conditions associated with PI3 kinase activity are described herein.

Abstract: The present invention provides chemical entities or compounds and pharmaceutical compositions thereof that are capable of modulating certain protein kinases such as mTor, tyrosine kinases, and/or lipid kinases such as PI3 kinase. Also provided in the present invention are methods of using these compositions to modulate activities of one or more of these kinases, especially for therapeutic applications.

Abstract: The invention provides a chemical entity of Formula (I), and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods, including metabolic and reaction kinetic studies, detection and imaging techniques, and radioactive treatments; and therapies, including inhibiting PDE4, enhancing neuronal plasticity, treating neurological disorders, providing neuroprotection, treating a cognitive impairment associated with a CNS disorder, enhancing the efficiency of cognitive and motor training, providing neurorecovery and neurorehabilitation, enhancing the efficiency of non-human animal training protocols, and treating peripheral disorders, including inflammatory and renal disorders.

Abstract: A heart valve implant may include a shaft and an anchor configured to be coupled to an end of the shaft. A spacer may be coupled to a portion of the shaft and comprise a plurality of individual segments including a first and at least a second individual segment. The first segment may be coupled to the shaft. The second segment may be coupled to at least a portion of an exterior surface of the first segment and may have at least one cross-section dimension which is greater than an internal cross-sectional dimension of a delivery lumen. Additional segments may be coupled to an inner, adjacent segment. The segments may include a collapsible body portion to facilitate percutaneously delivery through a lumen. The segments may define an outer surface of the spacer configured to interact with at least a portion of at least one cusp of a heart valve to at least partially restrict a flow of blood through the heart valve in a closed position.

Abstract: The present invention provides methods and compositions for selective modulation of certain protein kinases, and especially mTor complexes. The methods and compositions are particularly useful in inhibiting mTor selectively for therapeutic applications.